Compare DexCom, Inc. (DXCM) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs VICI Properties Inc — how do they compare? DexCom, Inc. trades at $83.67 (market cap $31.86B), while VICI Properties Inc trades at $22.94 (market cap $25.09B). The key difference: DexCom, Inc. is the larger of the two by market cap, and VICI Properties Inc pays a 8.07% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and VICI Properties Inc for 43 Days on average.
| DXCM | VICI | |
|---|---|---|
Market Cap | $31.86B | $25.09B |
Volume | 3,607,070 | 17,066,337 |
Sector | Health | Real Estate |
52-Week High | $92.34 | $31.42 |
52-Week Low | $54.84 | $22.53 |
Typical Hold Time | 62 Days | 43 Days |
Enterprise Value | $31.32B | $42.65B |
Dividend Yield | — | 8.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
VICI Properties trades at $22.88, down 1.06% with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and attractive valuation at 8.83 P/E. The stock shows mixed earnings performance with recent misses but maintains robust cash flow and dividend coverage. Recent news highlights tenant diversification through new leases while addressing market concerns about regional casino exposure and rising interest rates.
The investment case balances deep value metrics against sector headwinds, with analyst consensus strongly bullish ($28.90 target) but technical weakness suggesting near-term pressure. Key opportunities include the 7.8% dividend yield with 1.3x coverage, while risks center on tenant concentration and interest rate sensitivity in the REIT structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
